Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index; 23 of the 25 sources its claims cite were checked for support.
Abstract
Background Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin–kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high‐intensity statin therapy. Methods We conducted a multicenter, randomized, double‐blind, placebo‐controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low‐density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non‐high‐density lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high‐intensity dose or at the maximum tolerated dose. Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. Results The median duration of follow‐up was 2.8 years. A composite primary end‐point e…
Overview
CoChat Summary
TL;DR
In patients with a recent acute coronary syndrome receiving high-intensity or maximum-tolerated statin therapy, alirocumab reduced the risk of recurrent ischemic cardiovascular events compared with placebo. The benefit was driven mainly by the composite primary end point, with similar adverse-event rates except for more local injection-site reactions.
Key findings
- The primary composite end point occurred in 903 patients (9.5%) in the alirocumab group vs. 1052 patients (11.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.78 to 0.93; P<0.001); the 4-year Kaplan-Meier estimate was 12.5% vs. 14.5%, and 49 patients would need treatment for 4 years to prevent one primary event.
- Death from any cause occurred in 334 patients (3.5%) in the alirocumab group vs. 392 patients (4.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.73 to 0.98).
- Absolute benefit was greater among patients with baseline LDL cholesterol ≥100 mg/dL; in that nonprespecified subgroup, 16 patients (95% CI, 11 to 34) would need treatment for 4 years to prevent one primary event (P<0.001 for interaction).
- Adverse events were similar between groups except local injection-site reactions, which occurred in 3.8% of alirocumab patients vs. 2.1% of placebo patients (P<0.001).
Methods
- Multicenter, randomized, double-blind, placebo-controlled trial enrolling 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier and elevated atherogenic lipid levels despite high-intensity or maximum-tolerated statin therapy.
- Patients were randomly assigned 1:1 to subcutaneous alirocumab 75 mg every 2 weeks (9462 patients) or matching placebo (9462 patients), with blinded dose adjustment targeting LDL cholesterol 25 to 50 mg/dL.
- The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization; median follow-up was 2.8 years, with intention-to-treat Cox proportional-hazards analysis stratified by geographic region.
Limitations
- The paper states that a limitation of all three PCSK9 antibody trials, including this one, is infrequent use of ezetimibe because its cardiovascular efficacy was established after most patients had already been enrolled.
- The paper states that whether safety and efficacy were influenced by the blinded dose-adjustment strategy is unknown, and that neither this trial nor FOURIER can fully predict longer-term safety of PCSK9 monoclonal antibody treatment.
- Evident from the text: median follow-up was 2.8 years, limiting assessment of longer-term outcomes; the baseline LDL cholesterol ≥100 mg/dL subgroup finding was from a nonprespecified analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
15 Valid · 1 Not valid · 3 Not checked · 54 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol when administered alone or with a statin. 8-12”
What the sources say
- Supportedcites [8] 8. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366: 1108-18. source
The Discussion (page not supplied) states that REGN727 lowered LDL cholesterol both alone and in subjects already receiving atorvastatin. The Lipid and Lipoprotein Response section reports substantial reductions in the atorvastatin-treated groups. (LLM, conf=0.93)
- Could not verifycites [9] 9. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-99. sourceExperimental — accuracy not yet measured
The supplied copy contains repository metadata and a PDF listing, but no passage reporting LDL-cholesterol outcomes (Abstract listing). Searches for PCSK9 antibodies, alirocumab, LDL reduction, and use with or without a statin returned no matching passages. The claim therefore cannot be checked against our copy. (LLM, conf=0.78)
- Supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. source
The Efficacy End Points section reports substantial LDL-cholesterol reductions with the PCSK9 monoclonal antibody evolocumab both in the diet-alone group and in groups receiving atorvastatin. The paper also describes earlier trials of PCSK9 inhibitors that significantly reduced LDL cholesterol. (LLM, conf=0.92)
- Supportedcites [11] 11. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713-22. source
The Introduction (p. 1714) says PCSK9 monoclonal antibodies effectively lower LDL cholesterol and that evolocumab reduces it by approximately 60%. Its cited studies include both an anti-PCSK9 monotherapy trial and a trial adding evolocumab to statin therapy (References); the Discussion also reports a 59% reduction with statin therapy. (LLM, conf=0.88)
- Supportedcites [12] 12. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500-9. source
The paper describes PCSK9 monoclonal antibodies as very effective at lowering LDL cholesterol. Its End Points table includes evolocumab trials with no background lipid therapy and trials with statins; the Lipid Changes section reports a 61% LDL-cholesterol reduction with evolocumab versus standard therapy at 12 weeks. The reported reduction is pooled, not a separate estimate for each treatment setting. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events.”
What the sources say
- Partly supportedcites [1] 1. Fox KA, Goodman SG, Klein W, et al. Management of acute coronary syndromes - variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002; 23: 1177-89. sourceExperimental — accuracy not yet measured
The Results section (p. 1181) reports in-hospital reinfarction after acute coronary syndrome, supporting a risk of recurrent events during admission. The paper says six-month outcomes were collected (Data collection), but it does not report those results here, so it does not establish a high risk of recurrent events after discharge. (LLM, conf=0.80)
- Partly supportedcites [2] 2. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a longterm perspective. Eur Heart J 2015; 36: 1163-70. sourceExperimental — accuracy not yet measured
The Results report an 18.3% one-year risk of MI, stroke, or cardiovascular death after an index MI, and the Discussion says risk remained high in subsequent years. This supports the claim for patients after MI, but the study does not establish the same risk for all patients after acute coronary syndrome, a broader group. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Similarly, a recent meta-analysis showed that intensive lowering of LDL cholesterol (primarily with the use of statins) resulted in a mortality benefit that was observed only among patients with a baseline LDL cholesterol level of 100 mg or more per deciliter. 20”
What the sources say
- Supportedcites [20] 20. Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA 2018; 319: 1566-79. source
The All-Cause Mortality and Cardiovascular Mortality sections report mortality risk reductions with more intensive LDL-C lowering only in trials with baseline LDL-C levels of at least 100 mg/dL. The Study Selection and Patient Population section reports that 26 of the 34 trials used statin monotherapy, supporting “primarily with statins.” The threshold describes trial-level baseline LDL-C, rather than a demonstrated cutoff for individual patients. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A limitation of all three trials is the infrequent use of ezetimibe, for which cardiovascular efficacy was established 5 after most of the patients had already been enrolled and the trials were well under way.”
What the sources say
- Supportedcites [5] 5. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-97. source
The citation is attached to the assertion that ezetimibe’s cardiovascular efficacy was established. The Conclusions report improved cardiovascular outcomes when ezetimibe was added to statin therapy, and the Efficacy End Points section reports significantly fewer cardiovascular events. The timing relative to the citing authors’ three trials is their own framing, not a finding attributed to this source. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The current trial and the FOURIER trial showed similar improvements in composite cardiovascular outcomes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 70 mg or more per deciliter and whose average baseline LDL cholesterol level was approximately 90 mg per deciliter. 10”
What the sources say
- Partly supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
24 more claims · 3 with their cited sources checked
Create a free account to see all 73 claims and every source verdict.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 27
- The quote only partly states this claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the cumulative data from the FOURIER and ODYSSEY OUTCOMES trials suggest that PCSK9 inhibitors effectively lower LDL-C and cardiovascular risk in individuals with CAD regardless of diabetes mellitus status.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [126]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two RCTs have reported a beneficial effect on clinical endpoints in ASCVD patients without FH [119,120].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mAb PCSK9 inhibitors evolocumab and alirocumab lower LDLC levels by ∼60% and, when added to statin therapy, decrease the risk of major vascular events [119].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the FOURIER trial, which included 27 564 patients with atherosclerotic CV disease, the addition of evolocumab to statin therapy (69% high-intensity therapy) resulted in a 15% relative risk reduction of the composite primary endpoint throughout a 2.2 year follow-up.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the best evidence to support lower LDL cholesterol targets in people with diabetes and established cardiovascular disease derives from multiple large randomized trials investigating the benefi ts of adding nonstatin agents to statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [110]
Experimental — accuracy not yet measured
32 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Patients, Trial Regimen, and Follow-up
“In China, 613 patients underwent randomization from May 2016 through February 2017.”
§ Statistical Analysis
“In China, 614 patients underwent randomization after random assignment of the main trial cohort had been completed”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Missing data | 19 (<0.1) | 12 (<0.1) |”
Reported 0.1 · recomputed 0.200803
Citations
Cites
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citationRoffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citationEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citation2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.019 · Cited by 2,625
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Self-citation
Cited by
Items 901–1,000 of 3,636
PCSK9-directed therapies: an update
Katzmann, J. L., & Laufs, U. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000919 · Cited by 22
“…monoclonal antibodies evolocumab and alirocu-mab markedly reduce low-density lipoprotein cholesterol (LDL-C), are well tolerated, and led to a 15% relative reduction of risk for major adverse cardio-vascular events (MACE) in the FOURIER and ODYS-SEY Outcomes trials on top of statin therapy [1,2].”
BackgroundAgarwala, A., Asim, R., & Ballantyne, C. M. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01199-2 · Cited by 29
“…Risk (FOURIER) [5] and Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment with Alirocumab (ODYSSEY Outcomes) [6], and PCSK9 inhibition with the injectable small interfering RNA agent inclisiran has demonstrated LDL-C–lowering efficacy and safety [7] and is…”
New insights into the therapeutic options to lower lipoprotein(a)
Baragetti, A., Dalt, L. D., & Norata, G. D. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14254 · Cited by 22
Albuquerque, E. L., Fulco, U. L., Caetano, E. W. S., & Freire, V. N. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108774956.011 · Cited by 21
Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors
Choi, J. Y., & Na, J. O. (2019) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2019.8.2.183 · Cited by 23
Design of Organo-Peptides As Bipartite PCSK9 Antagonists
Burdick, D. J., Skelton, N. J., Ultsch, M. H., Beresini, M. H., Eigenbrot, C. W., Li, W., Zhang, Y., Nguyen, H. Q., Kong-Beltran, M., Quinn, J. G., et al. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.9b00899 · Cited by 21
Khan, S. U., & Michos, E. D. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100013 · Cited by 26
Admin, A., Roger, C., Buch, C., Muller, T., Leemput, J., Demizieux, L., Passilly‐Degrace, P., Çınar, R., Iyer, M. R., Kunos, G., et al. (2020) · Diabetes · doi:10.2337/db20-0078 · Cited by 26
Kalra, S., Chen, Z., Deerochanawong, C., Shyu, K., Tan, R., Tomlinson, B., & Yeh, H. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.56762 · Cited by 25
Recommendations to improve lipid control. Consensus document of the Spanish Society of Cardiology
Escobar, C., Anguita, M. P., Arrarte, V., Barrios, V., Cequier, A. R., Cosín-Sales, J., Egocheaga, I., de Sá, E. L., Masana, L., Pallarés‐Carratalá, V., et al. (2019) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2019.08.012 · Cited by 29
The German Lipoprotein Apheresis Registry-Summary of the eleventh annual report
Schettler, V. J. J., Selke, N., Jenke, S., Zimmermann, T. P., Schlieper, G., Bernhardt, W. M., Heigl, F., Grützmacher, P., Löhlein, I., Klingel, R., et al. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.118601 · Cited by 23
Ferri, N., Colombo, E., & Corsini, A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111371 · Cited by 27
“…ezetimibe, which reduces the intestinal uptake of dietary and biliary cholesterol by inhibiting the Niemann–Pick C1-like protein 1 (NPC1L1) or monoclonal antibodies anti-proprotein convertase subtilisin/kexin type 9 (PCSK9), further reduced the LDL-C levels and major cardiovascular events [3–5].”
Aggarwal, R., Bhatt, D. L., Steg, P. G., Miller, M. J., Brinton, E. A., Dunbar, R. L., Ketchum, S. B., Tardif, J., Martens, F. M. A. C., Ballantyne, C. M., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.038656 · Cited by 23
Self-citationShen, X., DiMario, S., & Philip, K. J. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01107-0 · Cited by 20
Chen, Q., Wu, G., Li, C., Qin, X., Liu, R., & Zhang, M. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00386-w · Cited by 22
Genomics of hypertriglyceridemia
Tada, H., Takamura, M., & Kawashiri, M. (2020) · Advances in clinical chemistry · doi:10.1016/bs.acc.2019.12.005 · Cited by 25
Visonà, A., Paoli, A. D., Fedeli, U., Tonello, D., Zalunardo, B., Zanatta, N., Martini, R., Pesavento, R., Cuppini, S., Prior, M., et al. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.02.033 · Cited by 22
Cardiovascular and metabolic disease in the liver transplant recipient
Kim, N. G., Sharma, A., & Saab, S. (2020) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2020.101683 · Cited by 27
Lipid-lowering therapies in peripheral artery disease: A review
Skeik, N., Nowariak, M. E., Smith, J. E., Alexander, J. Q., Manunga, J. M., Mirza, A. K., & Sullivan, T. M. (2020) · Vascular Medicine · doi:10.1177/1358863x20957091 · Cited by 23
Liang, Z., Chen, Q., Yang, F., Yan, X., Zhang, X., Xue, C., Fang, F., & Zhao, Q. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07079-6 · Cited by 23
“Another large RCT investigating alirocumab, the ODYSSEY trial [47], showed some differences in specific outcomes compared with the FOURIER trial.”
ResultŠkrha, J. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00905-8 · Cited by 30
New and Emerging lipid-lowering Therapy
Backes, J. M., & Hilleman, D. E. (2021) · Future Cardiology · doi:10.2217/fca-2020-0217 · Cited by 21
Umbrella Review on Non-Statin Lipid-Lowering Therapy
Beshir, S. A., Hussain, N., Elnour, A. A., & Said, A. S. A. (2021) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484211002943 · Cited by 23
“The need for subcutaneous injection and minor side effects such as influenza-like symptoms, nasopharyngitis, upper respiratory tract infection, rash, nausea, backache, arthralgia, and injection-site reactions, the high acquisition cost, and lack of long-term safety data are some of the drawbacks of using these drugs.(…”
BackgroundResultFamilial Hypercholesterolemia: Do HDL Play a Role?
Pedro‐Botet, J., Climent, E., & Benaiges, D. (2021) · Biomedicines · doi:10.3390/biomedicines9070810 · Cited by 23
“PCSK9 inhibitors have represented a substantial change in the clinical management of hypercholesterolemia, mainly in the FH population [76,77], due to their high lipid-lowering efficacy and their preventive effects in CVD [78,79].”
BackgroundArnold, S. V., Cannon, C. P., de Lemos, J. A., Rosenson, R. S., Ballantyne, C. M., Liu, Y., Alam, S., Mues, K. E., Bhatt, D. L., Kosiborod, M., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.020893 · Cited by 22
Self-citationNew Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia
Cesaro, A., Fimiani, F., Gragnano, F., Moscarella, E., Schiavo, A., Vergara, A., Akioyamen, L. E., D’Erasmo, L., Averna, M. R., Arca, M., et al. (2021) · Heart Failure Clinics · doi:10.1016/j.hfc.2021.07.008 · Cited by 23
Altschmiedová, T., Todorovová, V., Šnejdrlová, M., Šatný, M., & Češka, R. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01008-8 · Cited by 22
Genetic variants associated with sepsis
Engoren, M., Jewell, E. S., Douville, N. J., Moser, S. E., Maile, M. D., & Bauer, M. E. B. (2022) · PLoS ONE · doi:10.1371/journal.pone.0265052 · Cited by 28
“PCSK9 inhibitors lower LDL cholesterol and decrease incidence of strokes and myocardial infarction [26].”
BackgroundEffect of PCSK9 inhibitors on remnant cholesterol and lipid residual risk: The LIPID‐REAL registry
Cordero, A., Olmo, M. R. F., Quiroga, G. A. C., Romero‐Menor, C., Fácila, L., Seijas‐Amigo, J., Rondán, J., Sandín, M., Rodríguez‐Mañero, M., Mora, M. C. B., et al. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13863 · Cited by 22
May, L. T., Bartolo, B. A. D., Harrison, D. G., Guzik, T. J., Drummond, G. R., Figtree, G. A., Ritchie, R. H., Rye, K., & de Haan, J. B. (2022) · Clinical Science · doi:10.1042/cs20210862 · Cited by 24
Yang, Y., Kim, H., Kim, S., Moon, M. K., & Korean Society of Lipid and Atherosclerosis (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0448 · Cited by 26
“Recent trials evaluating the effects of the combination of statins and ezetimibe or proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with atherosclerotic CVD, such as the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) [13], Further Cardiovascular Outcomes…”
BackgroundDaring to dream: Targeting lipoprotein(a) as a causal and risk-enhancing factor
Koschinsky, M. L., Stroes, E. S. G., & Kronenberg, F. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106843 · Cited by 24
Periprocedural myocardial infarction and injury
Spagnolo, M., Occhipinti, G., Laudani, C., Greco, A., & Capodanno, D. (2024) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuae014 · Cited by 27
Triglycerides and cardiovascular risk: Apolipoprotein B holds the key
Stock, J. K. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.03.004 · Cited by 21
Peng, H., Sun, Z., Chen, H., Zhang, Y., Ding, X., Zhao, X.-Q., & Li, H. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.05.036 · Cited by 23
Khan, S. U., Riaz, H., Rahman, H., Khan, M. U., Khan, M. S., Alkhouli, M. A., Kaluski, E., Leucker, T. M., & Blaha, M. J. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.05.014 · Cited by 26
Unmet needs in the management of cardiovascular risk in inflammatory joint diseases
Castañeda, S., Vicente‐Rabaneda, E. F., García-Castañeda, N., Prieto-Pena, D., Dessein, P. H., & González-Gay, M. Á. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1699058 · Cited by 25
Sun, J., Lepor, N. E., Cantón, G., Contreras, L., Hippe, D. S., Isquith, D. A., Balu, N., Kedan, I., Simonini, A. A., Yuan, C., et al. (2021) · International journal of cardiac imaging · doi:10.1007/s10554-020-02115-w · Cited by 25
Bagepally, B. S., & Sasidharan, A. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-021-03242-6 · Cited by 22
“The safety and cardiovascular efficacy of the PCSK9 antibodies have been demonstrated in prospective cardiovascular outcome trials with evolocumab [12], alirocumab [17], and inclisiran [18] proving superior to placebo at reducing major adverse cardiovascular events (MACE) among patients with elevated cardiovascular ri…”
BackgroundPerera, K., Kam, N., Ademi, Z., Liew, D., & Zomer, E. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.08.013 · Cited by 22
Michaeli, D. T., Michaeli, J. C., Boch, T., & Michaeli, T. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01173-3 · Cited by 20
“2 Cholesterol-Lowering Strategy Triglyceride-Lowering Strategy Ezetimibe Evolocuma Alirocumab Icosapent Ethyl Fenofibrate Name IMPROVE-IT FOURIER ODYSSEY REDUCE-IT ACCORD Reference [1] [2] [3] [4] [5] Start date 2005 2012 2012 2011 2001 Size 18,144 patients 27,564 patients 18,924 patients 8,179 patients 5,518 patients…”
MethodOptimal Medical Management of Atherosclerotic Intracranial Stenosis
Wabnitz, A., & Turan, T. N. (2024) · Stroke · doi:10.1161/strokeaha.123.043633 · Cited by 24
Angoulvant, D., Granjeon-Noriot, S., Amarenco, P., Bastien, A., Béchet, E., Boccara, F., Boissel, J., Cariou, B., Courcelles, E., Diatchenko, A., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae254 · Cited by 28
Self-citationAlagaratnam, J., van Bremen, K., Behrens, G. M. N., Boccara, F., Cinque, P. M., Gisslén, M., Guaraldi, G., Konopnicki, D., Kowalska, J. D., Mallon, P. W. G., et al. (2025) · The Lancet HIV · doi:10.1016/s2352-3018(25)00047-5 · Cited by 36
Ballantyne, C. M., & Norata, G. D. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf606 · Cited by 26
The interrelations between PCSK9 metabolism and cholesterol synthesis and absorption
Silbernagel, G., Steiner, L. K., Hollstein, T., Fauler, G., Scharnagl, H., Stojaković, T., Schumann, F., Bölükbasi, B., März, W., Steinhagen‐Thiessen, E., et al. (2018) · Journal of Lipid Research · doi:10.1194/jlr.p088583 · Cited by 19
“and evolocumab, not only reduce LDL-cholesterol but also the risk of cardiovascular events (3, 4).”
BackgroundCurrent pharmacotherapies for atherosclerotic cardiovascular diseases
Park, J., & Oh, G. T. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01116-1 · Cited by 21
Leitner, D. R., Toplak, H., Kedenko, L., Steinmaurer, T., Gräff, V., Metzner, T., Schwaiger, E., & Prager, R. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1786678 · Cited by 21
Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes
Li, T., Yingyi, Z., & Cong, H. (2021) · BMC Cardiovascular Disorders · doi:10.1186/s12872-020-01827-0 · Cited by 22
Dyslipidemia and prevention of atherosclerotic cardiovascular disease in the elderly
LUCCHI, T. (2022) · Minerva Medica · doi:10.23736/s0026-4806.21.07347-x · Cited by 41
Chen, Y., Li, G., Guo, X., Ouyang, N., Li, Z., Ye, N., Yu, S., Yang, H., & Sun, Y. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10153388 · Cited by 22
“despite achieving an LDL-C level as a mean of 30–40 mg/dL with statins, ezetimibe, and/or proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors [5].”
BackgroundHilvo, M., Dhar, I., Lääperi, M., Lysne, V., Sulo, G., Tell, G. S., Jousilahti, P., Nygard, O. K., Brenner, H., Schöttker, B., et al. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab075 · Cited by 22
Keyes, E., Grinnell, M., Jacoby, D. S., Vazquez, T., Diaz, D., Werth, V. P., & Williams, K. J. (2021) · International Journal of Women’s Dermatology · doi:10.1016/j.ijwd.2021.08.015 · Cited by 21
High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better
Grundy, S. M., Stone, N. J., Blumenthal, R. S., Braun, L. T., Heidenreich, P. A., Lloyd-Jones, D., Orringer, C. E., Saseen, J. J., Smith, S. C., Sperling, L. S., et al. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.02.032 · Cited by 20
Low LDL-C level and intracranial haemorrhage risk after ischaemic stroke: a prospective cohort study
Xu, J., Chen, Z., Wang, M., Mo, J., Jing, J., Yalkun, G., Dai, L., Meng, X., Li, H., Li, Z., et al. (2022) · Stroke and Vascular Neurology · doi:10.1136/svn-2022-001612 · Cited by 20
Angina in 2022: Current Perspectives
Manfredi, R., Verdoia, M., Compagnucci, P., Barbarossa, A., Stronati, G., Casella, M., Russo, A. D., Guerra, F., & Ciliberti, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11236891 · Cited by 27
“Proprotein convertase subtilisin-kexin type 9 (PCSK-9) inhibitors alirocumab and evolocumab were both effective in reducing the risk of cardiovascular events in high-risk populations in the FOURIER and ODISSEY without significant safety concerns [38,39].”
BackgroundTargeting PCSK9 With Antibodies and Gene Silencing to Reduce LDL Cholesterol
Newman, C. B., & Tobert, J. A. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac708 · Cited by 20
Greco, A., Finocchiaro, S., Angiolillo, D. J., & Capodanno, D. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2171788 · Cited by 23
Two decades of vaccine development against atherosclerosis
Moreno‐Gonzalez, M. A., Ortega-Rivera, O. A., & Steinmetz, N. F. (2023) · Nano Today · doi:10.1016/j.nantod.2023.101822 · Cited by 22
Köenig, W., Ray, K. K., Landmesser, U., Leiter, L. A., Schwartz, G. G., Wright, R. S., Conde, L. G., Han, J., & Raal, F. J. (2023) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2023.100503 · Cited by 22
Self-citation2022 Saudi Guidelines for the Management of Dyslipidemia
Alrahimi, J. S., AlSaif, S. M., Alasnag, M. A., Awan, Z. A., Almutairi, F., Mudaiheem, H. Y. A., Gencer, B., Catapano, A. L., Mach, F., & Tash, A. A. (2023) · Heart Views · doi:10.4103/heartviews.heartviews_102_22 · Cited by 28
“A [74,76,77] For secondary prevention in patients at very high risk not achieving their goal on a maximum tolerated dose of a statin and ezetimibe, a combination with PCSK9 monoclonal antibodies is recommended I A [3] For the extremely f high‑risk patients, initiation of triple combination therapy…”
InfluentialDavies, A. J., Wenzl, F. A., Li, X. S., Winzap, P., Obeid, S., Klingenberg, R., Mach, F., Räber, L., Müller, O., Matter, C. M., et al. (2023) · International Journal of Cardiology · doi:10.1016/j.ijcard.2023.131261 · Cited by 22
Xu, R., Li, T., Luo, J., Zhang, X., Wang, T., Wang, Y., Ma, Y., Yang, B., Jia, J., Dmytriw, A. A., et al. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14640 · Cited by 20
Paciaroni, M., & Kamel, H. (2019) · Stroke · doi:10.1161/strokeaha.118.024160 · Cited by 21
Cannon, C. P., Khan, I., Klimchak, A. C., Sanchez, R. J., Sasiela, W. J., Massaro, J. M., D’Agostino, R. B., & Reynolds, M. R. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.06.005 · Cited by 20
Self-citationNew Insights in the Control of Low-Density Lipoprotein Cholesterol to Prevent Cardiovascular Disease
Katzmann, J. L., & Laufs, U. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1159-z · Cited by 20
Dressel, A., Schmidt, B., Schmidt, N., Laufs, U., Fath, F., Chapman, M. J., Grammer, T. B., & März, W. (2019) · Vascular Pharmacology · doi:10.1016/j.vph.2019.106566 · Cited by 22
PCSK9 inhibition in patients with heart transplantation: A case series
Sandesara, P. B., Dhindsa, D. S., Hirsh, B. J., Jokhadar, M., Cole, R. T., & Sperling, L. S. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.06.010 · Cited by 22
Drexel, H., Rosano, G. M. C., Lewis, B. S., Huber, K., Vonbank, A., Dopheide, J. F., MADER, A., Niessner, A., Savarese, G., Waßmann, S., et al. (2019) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz029 · Cited by 20
Robinson, J. G., Farnier, M., Kastelein, J. J. P., Roth, E. M., Taskinen, M., Colhoun, H. M., Brunet, A., DiCioccio, A. T., Lecorps, G., Pordy, R. C., et al. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.10.004 · Cited by 23
Self-citationA practical algorithm for the management of patients with statin-associated muscle symptoms
Rallidis, L. S. (2019) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2019.09.001 · Cited by 24
Burggraaf, B., Pouw, N. M. C., Fernández‐Arroyo, S., der Zee, L. C. V. V., van de Geijn, G. M., Birnie, E., Huisbrink, J., van der Zwan, E. M., Mulder, M. T., Rensen, P. C. N., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13960 · Cited by 22
Vaccines Targeting PSCK9 for the Treatment of Hyperlipidemia
Tóth, Š., Pella, D., & Fedačko, J. (2020) · Cardiology and Therapy · doi:10.1007/s40119-020-00191-6 · Cited by 24
“The next study made with a fully humanized antibody was an ODYSSEY Outcomes (Evaluation of Cardiovascular Outcomes After an ACS During Treatment With Alirocumab) trial that enrolled 18,924 volunteers who had an acute coronary syndrome in last 12 months and who did not reach the levels of LDL-C\70 mg/dl [17, 18].”
MethodHypercholesterolemia and cardiovascular disease: Focus on high cardiovascular risk patients
Watts, G. F., Catapano, A. L., Masana, L., Zambon, A., Pirillo, A., & Tokgözoğlu, L. S. (2020) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2021.01.006 · Cited by 28
Hwang, J., Choi, E., Choi, H., Park, J., & Chung, M. (2021) · Foods · doi:10.3390/foods10020408 · Cited by 21
“fully human anti‐PCSK9 monoclonal antibodies to evaluate the PCSK9‐mediated path‐ way [13,14].”
BackgroundRaccah, B. H., Yanovsky, A., Treves, N., Rotshild, V., Renoux, C., Danenberg, H. D., Eliaz, R., & Matok, I. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.04.025 · Cited by 23
Efficacy and Safety of Evinacumab for the Treatment of Hypercholesterolemia: A Meta-Analysis
Jin, M., Meng, F., Yang, W., Liang, L., Wang, H., & Zhenyan, F. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001073 · Cited by 22
Remnant Cholesterol: The Leftovers and Their Contribution to Atherosclerotic Cardiovascular Disease
Bruemmer, D., & Cho, L. (2021) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.121.012615 · Cited by 21
Low-density lipoprotein cholesterol goal attainment in Germany: Results from the DA VINCI study
Gouni-Berthold, I., Schaper, F., Schatz, U., Tabbert-Zitzler, A., Fraass, U., Sauer, S., & Ray, K. K. (2022) · Atherosclerosis Plus · doi:10.1016/j.athplu.2022.07.024 · Cited by 19
The Basics of Metabolic Dysfunction–Associated Steatotic Liver Disease for Cardiologists
Khan, M. S., Javaid, S. S., Dinani, A. M., Wegermann, K., Pandey, A., Bhatt, A. S., Muthiah, M. D., Spall, H. G. C. V., Zannad, F. M., Butler, J., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.100 · Cited by 24
Rifai, M. A., Jia, X., Al-Mallah, M. H., Miedema, M. D., Martin, S. S., & Virani, S. S. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0789-3 · Cited by 20
Ohm, J., Hjemdahl, P., Skoglund, P. H., Discacciati, A., Sundström, J., Hambræus, K., Jernberg, T., & Svensson, P. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.07.001 · Cited by 19
Danchin, N., Farnier, M., Zeller, M., Puymirat, É., Cottin, Y., Belle, L., Lemesle, G., Cayla, G., Ohlmann, P., Jacquemin, L., et al. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.03.008 · Cited by 21
Bias and Loss to Follow‐Up in Cardiovascular Randomized Trials: A Systematic Review
Fong, L. C. W., Ford, T. J., da Costa, B. R., Jüni, P., & Berry, C. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015361 · Cited by 19
Recomendaciones preventivas cardiovasculares. Actualización PAPPS 2020
Orozco‐Beltrán, D., Cuixart, C. B., Sánchez, J. J. A., Banegas, J. R., Cuenca, A. M. C., Gil-Guillén, V. F., Rioboó, E. M., & Pérez, J. N. (2020) · Atención Primaria · doi:10.1016/j.aprim.2020.08.002 · Cited by 30
Blaum, C. M., Seiffert, M., Goßling, A., Kroeger, F., Bay, B., Lorenz, T., Braetz, J., Graef, A., Zeller, T., Schnabel, R. B., et al. (2020) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa088 · Cited by 19
Klassen, A., Faccio, A. T., Picossi, C. R. C., Derogis, P. B. M. C., Ferreira, C. E. D. S., Lopes, A. S., Sussulini, A., Cruz, E. C. S., Bastos, R. T., Fontoura, S. C., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-95455-z · Cited by 18
Salsalate reduces atherosclerosis through AMPKβ1 in mice
Day, E. A., Ford, R. J., Smith, B. K., Houde, V. P., Stypa, S., Rehal, S., Lhoták, Š., Kemp, B. E., Trigatti, B. L., Werstuck, G. H., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101321 · Cited by 20
Schwartz, G. G., & Giugliano, R. P. (2022) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000830 · Cited by 19
Self-citationSikorski, V., Vento, A. E., & Kankuri, E. M. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.07.018 · Cited by 28
From genetic variation to precision medicine
Sergouniotis, P. I., Fitzgerald, T. W., & Birney, E. (2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2022.11 · Cited by 22
Sun, L., Wolska, A. T., Amar, M. J., Zubirán, R., & Remaley, A. T. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad153 · Cited by 27
Sayed, A., Shazly, O., Slipczuk, L., Krittanawong, C., Baloch, F., & Virani, S. S. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-023-07474-9 · Cited by 19
Chen, T., Wang, Z., Xie, J., Xiao, S., Li, W., & Liu, N. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.05.033 · Cited by 20
Biccirè, F. G., Gatto, L., Porta, Y. L., Pignatelli, P., Prati, F., & Pastori, D. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10060260 · Cited by 23
“As aforementioned, substantial data have shown that the use of monoclonal antibodies inhibiting PCSK9 has been able to further reduce LDL-C levels and improve clinical outcomes when added to statin therapy [11,12].”
BackgroundResultInfluentialRecent advances in the management and implementation of care for familial hypercholesterolaemia
Lan, N. S. R., Bajaj, A., Watts, G. F., & Cuchel, M. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106857 · Cited by 22
Siniawski, D. A., Masson, G., Masson, W. M., Barbagelata, L., Destaville, J., Lynch, S., Vitagliano, L., Parodi, J. B., Berton, F., Indavere, A., et al. (2023) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2023.200198 · Cited by 19
Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol
Mohamed, F., Mansfield, B. S., & Raal, F. J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12155082 · Cited by 22
“The FOURIER trial demonstrated that evolocumab reduced the risk of major adverse cardiovascular events compared to a placebo, and the ODYSSEY OUTCOMES trial showed similar results with alirocumab, with greater benefit seen in patients with higher baseline LDL-C levels [57,58].”
ResultData-driven transcriptomics analysis identifies PCSK9 as a novel key regulator in liver aging
Arif, M., Mátyás, C., Mukhopadhyay, P., Yokus, B., Trojnár, E., Pálóczi, J., Paes‐Leme, B., Zhao, S., Lohoff, F. W., Haskó, G., et al. (2023) · GeroScience · doi:10.1007/s11357-023-00928-w · Cited by 21
“Over the past decade, the FDA has granted approval for several monoclonal antibodies inhibiting PCSK9 (e.g., Alirocumab) [46], and recently a small interfering RNA (Inclisiran) [47] that inhibits PCSK9 synthesis in the liver for the treatment of hypercho-lesterolemia and reduction of related…”
BackgroundDrug intervention as an emerging concept for secondary prevention in patients with coronary disease
Minami, Y., Ako, J., Tsujita, K., Yokoi, H., Ikari, Y., Morino, Y., Kobayashi, Y., & Kozuma, K. (2024) · Cardiovascular Intervention and Therapeutics · doi:10.1007/s12928-024-00994-7 · Cited by 24
“Recently, the clinical efficacy of ezetimibe and proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) on top of statin-based conventional lipid-lowering therapy among patients with atherogenic cardiovascular disease has been demonstrated in randomized trials [5–7].”
Metadata
- Authors
- Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., Lecorps, G., Mahaffey, K. W., Moryusef, A., Pordy, R., Quintero, K., Roe, M. T., Sasiela, W. J., Tamby, J.-F., Tricoci, P., White, H. D., & Zeiher, A. M.
- Affiliations
- Inserm (FR)
- From the Division of Cardiology, University of Colorado School of Medicine, Aurora (G.G.S.); Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Paris Diderot University, Sorbonne Paris Cité, FACT (French Alliance for Cardiovascular Trials), and INSERM Unité 1148 (P.G.S.), and Sanofi (C.H., G.L.) — all in Paris; the National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London (P.G.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.), and...
- State University of New York (US)
- Brigham and Women's Hospital (US)
- St. Michael's Hospital (CA)
- Goethe University Frankfurt (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11-29
- Volume
- 379
- Issue
- 22
- Pages
- 2097-2107
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899997727
- Semantic Scholar
- 3bd18f4d47c498a70a737151f3b2a9a1a09050bd
- Cited by
- 3,634
- References
- 22
- Citations by year
- 2026: 452 · 2025: 403 · 2024: 450 · 2023: 446 · 2022: 471 · 2021: 473 · 2020: 481 · 2019: 414 · 2018: 31
- FWCI
- 363.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- Lanzhou University Institutional Repository (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lirias (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Griffith Research Online (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Sanofi
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- alirocumab, PCSK9 inhibitors, acute coronary syndrome, cardiovascular outcomes, LDL cholesterol lowering, high-intensity statin therapy, LDL cholesterol targets, cardiovascular mortality, myocardial infarction, ischemic stroke, unstable angina, apolipoprotein B, non-HDL cholesterol, secondary prevention, cardiovascular risk reduction, LDL-C lowering therapy
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Adult, Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Acute Coronary Syndrome, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

